Predictive Oncology Inc. Files 8-K for Material Agreement

Ticker: AGPU · Form: 8-K · Filed: Feb 19, 2025 · CIK: 1446159

Sentiment: neutral

Topics: material-agreement, equity-sale, corporate-filing

Related Tickers: PRED

TL;DR

PRED filed an 8-K for a material definitive agreement - big news incoming.

AI Summary

Predictive Oncology Inc. announced on February 18, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events, filing these details as part of its Form 8-K.

Why It Matters

This filing indicates significant corporate activity, potentially involving new partnerships, financing, or strategic shifts for Predictive Oncology Inc.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and unregistered equity sales can dilute existing shareholders.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Predictive Oncology Inc.?

The filing does not specify the details of the material definitive agreement, only that one was entered into on February 18, 2025.

When was the Form 8-K filed?

The Form 8-K was filed as of February 19, 2025.

What were Predictive Oncology Inc.'s former company names?

Predictive Oncology Inc. was formerly known as Precision Therapeutics Inc. (twice) and Skyline Medical Inc.

In which state is Predictive Oncology Inc. incorporated?

Predictive Oncology Inc. is incorporated in Delaware.

What other items are reported in this 8-K filing besides the material agreement?

The filing also reports on unregistered sales of equity securities, other events, and financial statements and exhibits.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 19, 2025 regarding Predictive Oncology Inc. (AGPU).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing